NEW YORK (Reuters Health) Jan. 3 A report in the
Journal of the American Dental Association for January clarifies the risk of jaw osteonecrosis associated with bisphosphonates. Intravenous bisphosphonates strongly increase the risk of adverse jaw outcomes, but oral bisphosphonates tend to decrease the risk, the research shows.